What's Happening?
CellCentric, a biotech company with operations in the U.K. and U.S., has secured $220 million in a Series D funding round. This marks the largest private biotech financing in Europe for 2026. The funds
will support the development of inobrodib, an investigational small molecule targeting advanced blood cancer. The company plans to initiate a Phase 3 trial for multiple myeloma in late 2026. The ongoing Phase 2 trial has shown promising results, with inobrodib demonstrating increased response rates compared to existing therapies. The funding will also facilitate further studies and potential expansion into new treatment combinations.
Why It's Important?
The significant investment in CellCentric underscores the growing interest in innovative cancer treatments. Inobrodib's development could offer a new therapeutic option for patients with advanced multiple myeloma, a condition with limited treatment options. The funding highlights the potential of biotech innovations to address unmet medical needs and improve patient outcomes. Successful development of inobrodib could enhance CellCentric's market position and contribute to advancements in cancer therapy. The investment also reflects confidence in the biotech sector's ability to deliver groundbreaking treatments.
What's Next?
CellCentric will focus on advancing inobrodib through clinical trials, with a Phase 3 trial scheduled for the second half of 2026. The company aims to achieve regulatory approval and bring the treatment to market. Continued collaboration with partners and stakeholders will be crucial for the successful development and commercialization of inobrodib. The biotech industry will be watching closely as CellCentric progresses, potentially setting new standards for cancer treatment and biomanufacturing.
